These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32988842)

  • 21. An "On Demand" canakinumab regimen for treating children with Colchicine-Resistant familial Mediterranean fever - A multicentre study.
    Shehadeh K; Levinsky Y; Kagan S; Zuabi T; Tal R; Aviran NH; Butbul Aviel Y; Tirosh I; Spielman S; Miller-Barmak A; Semo Oz R; Harel L; Chodick G; Amarilyo G
    Int Immunopharmacol; 2024 May; 132():111967. PubMed ID: 38569431
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Canakinumab treatment in children with familial Mediterranean fever: report from a single center.
    Yazılıtaş F; Aydoğ Ö; Özlü SG; Çakıcı EK; Güngör T; Eroğlu FK; Gür G; Bülbül M
    Rheumatol Int; 2018 May; 38(5):879-885. PubMed ID: 29450637
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Canakinumab treatment in four children with colchicine resistant familial mediterranean fever.
    Ozkan S; Atas B
    J Pak Med Assoc; 2017 Jun; 67(6):945-947. PubMed ID: 28585601
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Approach to the patients with inadequate response to colchicine in familial Mediterranean fever.
    Gül A
    Best Pract Res Clin Rheumatol; 2016 Apr; 30(2):296-303. PubMed ID: 27886801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Case report: Successful treatment with canakinumab of a patient with active ileitis associated with familial Mediterranean fever.
    Kishida D; Hara R; Ichikawa T; Iwaya M; Shimojima Y; Sekijima Y
    Int J Rheum Dis; 2024 Jan; 27(1):e15006. PubMed ID: 38069585
    [No Abstract]   [Full Text] [Related]  

  • 26. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis.
    Varan Ö; Kucuk H; Babaoglu H; Guven SC; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
    Mod Rheumatol; 2019 Mar; 29(2):363-366. PubMed ID: 29578360
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience.
    Kavrul Kayaalp G; Çağlayan Ş; Demirkan FG; Guliyeva V; Otar Yener G; Öztürk K; Demir F; Özdel S; Çakan M; Sönmez HE; Sözeri B; Aktay Ayaz N
    Pediatr Rheumatol Online J; 2023 Nov; 21(1):140. PubMed ID: 37996934
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anti-IL-1 treatment in familial Mediterranean fever and related amyloidosis.
    Özçakar ZB; Özdel S; Yılmaz S; Kurt-Şükür ED; Ekim M; Yalçınkaya F
    Clin Rheumatol; 2016 Feb; 35(2):441-6. PubMed ID: 25213327
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Total Hip Joint Replacement in a Patient with Colchicine-Resistant Familial Mediterranean Fever under Canakinumab Treatment.
    Matsumoto H; Ohashi H; Fujita Y; Yoshida S; Yokose K; Temmoku J; Matsuoka N; Shinden Y; Kusano K; Sonobe T; Nakamoto Y; Yashiro-Furuya M; Asano T; Sato S; Suzuki E; Yago T; Watanabe H; Migita K
    Tohoku J Exp Med; 2022 Feb; 256(2):169-174. PubMed ID: 35236806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-life data on tapering or discontinuation of canakinumab therapy in patients with familial Mediterranean fever.
    Karabulut Y; Gezer HH; Öz N; Esen İ; Duruöz MT
    Rheumatol Int; 2022 Dec; 42(12):2211-2219. PubMed ID: 36048189
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term safety and efficacy of anakinra and canakinumab in patients with familial Mediterranean fever: a single-centre real-life study with 101 patients.
    Atas N; Eroglu GA; Sodan HN; Ozturk BO; Babaoglu H; Satis H; Karadeniz H; Guler AA; Salman RB; Goker B; Ozturk MA; Haznedaroglu S; Tufan A
    Clin Exp Rheumatol; 2021; 39 Suppl 132(5):30-36. PubMed ID: 34251317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interventions for reducing inflammation in familial Mediterranean fever.
    Wu B; Xu T; Li Y; Yin X
    Cochrane Database Syst Rev; 2018 Oct; 10(10):CD010893. PubMed ID: 30338514
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic therapy in familial Mediterranean fever.
    Koga T; Migita K; Kawakami A
    Mod Rheumatol; 2016 Sep; 26(5):637-41. PubMed ID: 26939747
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The efficacy of anti- IL-1 treatment in three patients with coexisting familial Mediterranean fever and multiple sclerosis.
    Ozdogan H; Ugurlu S; Uygunoglu U; Tutuncu M; Gul A; Akman G; Siva A
    Mult Scler Relat Disord; 2020 Oct; 45():102332. PubMed ID: 32645635
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study.
    Brik R; Butbul-Aviel Y; Lubin S; Ben Dayan E; Rachmilewitz-Minei T; Tseng L; Hashkes PJ
    Arthritis Rheumatol; 2014 Nov; 66(11):3241-3. PubMed ID: 25049046
    [No Abstract]   [Full Text] [Related]  

  • 36. Long-term effectiveness and safety of canakinumab in pediatric familial Mediterranean fever patients.
    Gülez N; Makay B; Sözeri B
    Mod Rheumatol; 2020 Jan; 30(1):166-171. PubMed ID: 30556769
    [No Abstract]   [Full Text] [Related]  

  • 37. Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases.
    Çakan M; Karadağ ŞG; Ayaz NA
    Turk J Pediatr; 2020; 62(2):167-174. PubMed ID: 32419407
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of the Auto-inflammatory Disease Activity Index to monitor disease activity in patients with colchicine-resistant Familial Mediterranean Fever, Mevalonate Kinase Deficiency, and TRAPS treated with canakinumab.
    Koné-Paut I; Piram M; Benseler S; Kuemmerle-Deschner JB; Jansson A; Rosner I; Tommasini A; Murias S; Karadag O; Levy J; McCreddin S; Migliaccio M; De Benedetti F
    Joint Bone Spine; 2022 Nov; 89(6):105448. PubMed ID: 35944600
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Familial Mediterranean fever, review of the literature.
    Alghamdi M
    Clin Rheumatol; 2017 Aug; 36(8):1707-1713. PubMed ID: 28624931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Canakinumab as monotherapy for treatment of familial Mediterranean fever - first report in Central and Eastern Europe region.
    Jesenak M; Hrubiskova K; Kapustova L; Kostkova M; Banovcin P
    Bratisl Lek Listy; 2018; 119(4):198-200. PubMed ID: 29663815
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.